Momentum Builds To Move Comparative Effectiveness From Idea To Action
This article was originally published in The Tan Sheet
Executive Summary
Drug and medical device industry efforts to restrict comparative effectiveness research from morphing into outright cost comparisons might be a losing battle, according to speakers at an industry conference
You may also be interested in...
Comparative Effectiveness Language Clarified In Compromise Stimulus Bill
Congress took steps in its final version of the economic stimulus package to alleviate concerns that the comparative effectiveness research provisions will lead to the government making cost-based comparisons or making coverage and reimbursement decisions based on the research
Comparative Effectiveness Bill Could Mean Opportunities For OTC Sponsors
Interest on Capitol Hill in comparative effectiveness research could lead to opportunities for marketers of OTC drugs that compete with prescription drugs or other interventions
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC